Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

• Main Authors: Max Robles-Nasta (Author), Daniela Sánchez-Bonilla (Author), Moises M. Gallardo-Pérez (Author), Edgar J. Hernández-Flores (Author), Merittzel A. Montes-Robles (Author), María de L. Pastelín-Martínez (Author), Juan C. Olivares-Gazca (Author), Guillermo J. Ruiz-Delgado (Author), Guillermo J. Ruiz-Argüelles (Author)
• Format: Book
• Published: Permanyer, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias. Tyrosine-kinase inhibitors are considered front-line therapy in high-income countries, whereas allogeneic hemato...